Peptide Inhaled Formulation Outsourcing: DPI, MDI, and Pulmonary Delivery Guide

Inhaled delivery is one of the most promising routes for peptide drugs. It offers fast absorption, avoids first pass metabolism, and can target the lungs directly for respiratory diseases, per WHO essential medicines.

But making a peptide work in an inhaled product is not easy. Peptides are fragile molecules that can break down during the formulation process, in the device, or in the lungs.

That is why formulation directors and inhalation scientists are turning to outsourcing partners. The right partner brings deep expertise in dry powder inhalers (DPI), metered dose inhalers (MDI), and aerosol testing that most companies do not have in house.

What Is Peptide Inhaled Formulation Development?

Peptide inhaled formulation development is the process of turning a peptide drug into a product that patients can breathe into their lungs. This involves choosing the right device, creating a stable formulation, and proving that the drug reaches the right part of the lung.

There are two main device types used for inhaled peptides. Dry powder inhalers (DPI) deliver the drug as a fine powder, while metered dose inhalers (MDI) use a propellant to push the drug out as a spray.

Each device type comes with its own set of formulation challenges. DPI products need the peptide to be milled or spray dried into particles small enough to reach the deep lung, usually between 1 and 5 microns.

MDI products require the peptide to be suspended or dissolved in a propellant system. The peptide must stay stable in this system over the full shelf life of the product.

A third option, nebulizers, can also deliver peptide solutions. But DPI and MDI are more portable and easier for patients to use, so they are the focus of most new programs.

"The lung offers a large absorptive surface area and thin epithelial barrier, making it an attractive route for systemic delivery of peptides and proteins.", Nitesh K. Kunda, Associate Professor of Pharmaceutical Sciences, Journal of Controlled Release (2024)

Why It Matters

The global inhaled drug market is worth over $40 billion and growing every year. Peptides are a key part of this growth because they can treat diseases that small molecules cannot.

Pulmonary delivery of peptides is especially useful for lung diseases like asthma, COPD, pulmonary fibrosis, and lung infections. But it also works for systemic delivery of peptides that treat diabetes, pain, and other conditions.

The main benefit of inhaled delivery is speed. Drugs reach the bloodstream through the lungs in minutes, much faster than oral delivery. This makes inhaled peptides a good option for conditions that need quick onset of action.

However, the lung is a tough environment for peptides. Enzymes in the lung tissue can break down peptides before they work. Mucus can trap them, and the immune system can clear them.

Outsourcing to a partner with inhalation expertise solves many of these problems. These partners have the equipment, the know-how, and the regulatory experience to get your product right.

Spray-dried peptide powders for DPI formulations can achieve fine particle fractions above 60%, but only when process parameters like inlet temperature and feed rate are tightly optimized for each specific peptide sequence.

Benefits Checklist

• Specialized equipment access: Use cascade impactors, laser diffraction tools, and inhalation testing rigs without buying them.
• Faster development: Skip the learning curve and work with scientists who have done this before.
• Device expertise: Get guidance on DPI vs. MDI selection based on your peptide's properties.
• Regulatory compliance: Meet FDA and EMA requirements for aerosol characterization and device testing.
• Cost savings: Avoid building a dedicated inhalation lab, which can cost millions of dollars.
• Stability testing: Access climate chambers and long term storage facilities for ICH stability studies.
• Scale up support: Move from lab scale to pilot and commercial scale with a partner who knows the process.
• Particle engineering: Use spray drying, jet milling, or other techniques to get the right particle size.

Before selecting an outsourcing partner for inhaled peptide work, confirm they have in-house cascade impactor testing (NGI or ACI) and experience with peptide-specific stability challenges, since aerosol characterization is a regulatory bottleneck that delays most first-time programs.

Services Breakdown

Service Area	What It Covers	Key Deliverables
Formulation Screening	Testing different excipients and peptide forms for inhalation	Lead formulation candidates
Particle Engineering	Spray drying, micronization, or jet milling to hit target particle size	Particle size distribution data
Device Selection	Evaluating DPI, MDI, or nebulizer platforms for your peptide	Device recommendation report
Aerosol Characterization	Cascade impactor testing, delivered dose uniformity, fine particle fraction	Full aerosol performance data
Stability Studies	ICH and accelerated stability testing of the drug product in the device	Stability data package
Analytical Method Development	HPLC, mass spec, and other methods for potency, purity, and degradation	Validated analytical methods
Device and Formulation Optimization	Iterating on the formulation and device to improve performance	Optimized product prototype
Regulatory Support	CMC sections for IND, NDA, or ANDA filings	Regulatory documents

The fine particle fraction (FPF) is one of the most important measures for inhaled products. It tells you what percentage of the drug is small enough to reach the deep lung. For most peptide inhalers, the target FPF is between 30% and 60%. Getting above 50% is considered excellent.

Tips for Success

1. Start with a solid understanding of your peptide's physical and chemical properties. Factors like solubility, melting point, and moisture sensitivity will drive your formulation approach.
2. Choose your device type early in development. Switching from DPI to MDI later can add a year or more to your timeline.
3. Test your peptide's stability in the presence of common inhalation excipients like lactose, leucine, and magnesium stearate.
4. Use cascade impactor testing (such as the Next Generation Impactor) from the start. This gives you the aerosol data regulators will ask for.
5. Plan for humidity and temperature effects on your powder or suspension. Inhaled products are highly sensitive to environmental conditions.
6. Work with your outsourcing partner to design a device that patients can use correctly. Poor device design leads to poor drug delivery and bad clinical outcomes.
7. Build a strong analytical package early. You will need validated methods for assay, content uniformity, degradation products, and moisture content.
8. Ask your partner about their experience with peptide-specific challenges like aggregation, oxidation, and deamidation in inhaled formulations.

Comparison Table

Factor	DPI (Dry Powder Inhaler)	MDI (Metered Dose Inhaler)
Drug Form	Dry powder	Suspension or solution in propellant
Particle Size Control	Spray drying or milling	Micronization or nano-milling
Device Complexity	Simpler, breath activated	More complex, requires coordination
Patient Ease of Use	Moderate (needs strong breath)	Moderate (needs hand-breath coordination)
Peptide Stability Risk	Moisture sensitivity	Propellant compatibility
Excipient Options	Lactose, mannitol, leucine	Surfactants, co-solvents
Cost of Goods	Generally lower	Generally higher (propellant costs)
Regulatory Path	Well established	Well established
Typical Fine Particle Fraction	30% to 50%	25% to 45%

If your team is also exploring other delivery routes for peptides, our guide on peptide drug delivery systems covers the full range of options from injectable to transdermal.

For teams working on nasal delivery as an alternative to pulmonary, check out our resource on peptide intranasal delivery formulation to compare the two approaches.

Particles between 1 and 5 microns in diameter are the ideal size for reaching the deep lung (the alveolar region). Particles larger than 5 microns tend to deposit in the throat and upper airways. Particles smaller than 0.5 microns are often exhaled without depositing at all. This narrow window makes particle engineering one of the most critical steps in inhaled peptide development.

Successful inhaled peptide formulation requires tight integration of device engineering, particle science, and peptide stability expertise, making specialized outsourcing partners essential for teams without deep inhalation experience.

Frequently Asked Questions

What types of peptides work best for inhaled delivery?

Peptides that are stable in dry form and have a molecular weight below about 10,000 daltons tend to work well for inhaled delivery. Smaller peptides pass through the lung membrane more easily. Peptides that are sensitive to moisture or heat may need special formulation approaches like spray drying with stabilizing excipients.

How is aerosol characterization done for peptide inhalers?

Aerosol characterization uses a cascade impactor, most commonly the Next Generation Impactor (NGI). The device separates inhaled particles by size and measures how much drug lands at each stage. This data gives you the fine particle fraction, the mass median aerodynamic diameter (MMAD), and the geometric standard deviation (GSD). These are all required by regulators.

What are the biggest challenges in inhaled peptide formulation?

The top challenges are peptide degradation during processing, moisture sensitivity of dry powders, achieving the right particle size, and ensuring the peptide stays stable in the device over the product's shelf life. Aggregation and loss of biological activity are also common issues that need to be addressed early in development.

How long does it take to develop an inhaled peptide product?

A typical program takes 2 to 4 years from formulation screening through to a clinical supply of the drug product. The timeline depends on how many formulation iterations are needed, the complexity of the device, and the regulatory requirements for your target market.

Is DPI or MDI better for peptide drugs?

Neither is always better. DPI is often preferred because it avoids the need for propellants and the peptide stays in dry form, which is usually more stable. MDI may be better if your peptide is very potent and needs precise dose control. Your outsourcing partner can help you evaluate both options based on your peptide's unique properties.

What regulatory requirements apply to inhaled peptide products?

The FDA requires aerosol characterization data, delivered dose uniformity testing, and device performance data as part of your CMC package. You must also follow the FDA's guidance on metered dose inhaler and dry powder inhaler drug products. The EMA has similar requirements outlined in their guideline on pharmaceutical quality of inhalation and nasal products.

How do I choose the right outsourcing partner for inhaled peptide work?

Look for a partner with a dedicated inhalation lab, experience with peptide molecules, and a full set of aerosol testing equipment. Ask about their track record with IND or NDA filings for inhaled products. Make sure they can handle both formulation development and analytical testing under one roof to avoid data transfer issues.